Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
ImmunityBio, Inc. - Common Stock
(NQ:
IBRX
)
2.710
+0.030 (+1.12%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about ImmunityBio, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
LA Times Going Public? Patrick Soon-Shiong Plans Green Bay-Style Ownership To 'Democratize' 143-Year-Old Paper
Today 2:36 EDT
Los Angeles Times owner Patrick Soon-Shiong announced plans to take the 143-year-old newspaper public within the next year.
Via
Benzinga
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
July 09, 2025
Via
Investor Brand Network
Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers
July 09, 2025
EQNX::TICKER_START (NYSE:CLDI),(NASDAQ:VRTX),(NASDAQ:IBRX),(NASDAQ:CRSP),(NASDAQ:CTMX) EQNX::TICKER_END
Via
FinancialNewsMedia
Topics
Death
UK MHRA Approves ImmunityBio’s ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In Situ
July 07, 2025
From
ImmunityBio, Inc.
Via
Business Wire
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
June 03, 2025
From
ImmunityBio, Inc.
Via
Business Wire
Vera Therapeutics, Applied Digital, Kymera Therapeutics And Other Big Stocks Moving Higher On Monday
June 02, 2025
Via
Benzinga
ImmunityBio Receives FDA Expanded Access Authorization for Landmark Treatment of Lymphopenia With ANKTIVA®, the Cancer BioShield™ Platform, in Patients With Solid Tumors
June 02, 2025
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East
May 27, 2025
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Short Interest Hits 2-Month High, Yet Retail Traders Bet On The Upside
May 18, 2025
Retail traders showed bullish sentiment following strong Q1 revenue growth and positive clinical data for its bladder cancer drug, despite a 54% jump in short interest.
Via
Stocktwits
Foot Locker And Archer Aviation Are Among Top 8 Mid-Cap Gainers Last Week (May 12-May 16): Are The Others In Your Portfolio?
May 18, 2025
Top mid-cap stock performers last week: Foot Locker, Inc. (FL), Archer Aviation Inc. (ACHR), DigitalBridge Group, Inc. (DBRG), NuScale Power Corporation (SMR), Diginex Limited (DGNX), ImmunityBio, Inc....
Via
Benzinga
ImmunityBio Reports Doubled Net Revenue and 150% Unit Growth in Q1 2025, With Continued Strong Sales Momentum in First Quarter since J-code
May 12, 2025
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Stock Tumbles 18% After FDA Issues Refuse To File Letter: But Retail’s Positive
May 05, 2025
ImmunityBio received an RTF letter regarding a supplemental biologics license application it filed for the use of ANKTIVA plus Bacillus Calmette-Guerin (BCG) in a specific case scenario of non-muscle...
Via
Stocktwits
12 Health Care Stocks Moving In Monday's Intraday Session
May 05, 2025
Via
Benzinga
ImmunityBio Slapped With FDA Refusal To File Letter For Expanded Use Of Its Bladder Cancer Drug
May 05, 2025
ImmunityBio's ANKTIVA sBLA for papillary bladder cancer was rejected by the FDA despite prior support, prompting the company to request urgent talks.
Via
Benzinga
Netflix, CNA Financial And Other Big Stocks Moving Lower In Monday's Pre-Market Session
May 05, 2025
Via
Benzinga
ImmunityBio Requests an Urgent Meeting With FDA to Address the Change in the Agency’s Unambiguous Guidance on Jan 2025 to Submit a sBLA for NMIBC BCG Unresponsive Papillary Disease, Following an Inconsistent Refusal to File Letter on May 2, 2025
May 05, 2025
From
ImmunityBio, Inc.
Via
Business Wire
Unmatched Long-Term Bladder Preservation for 36 Months in over 80 percent of Responders with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC CIS and Papillary Disease Alone – Best in Disease and Best in Class with 5 Year Follow-Up
April 28, 2025
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
April 21, 2025
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces FDA Submissions of Supplemental BLA for NMIBC Papillary Disease and for Expanded Access of ANKTIVA® to Treat Lymphopenia
April 15, 2025
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces Execution of $75 Million Equity Financing with an Institutional Investor
April 08, 2025
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio to Host Key Opinion Leader and Investor Meeting to Provide Updates on Clinical Programs and ANKTIVA Commercial Launch
April 07, 2025
From
ImmunityBio, Inc.
Via
Business Wire
Concentrix Posts Better-Than-Expected Earnings, Joins Soleno Therapeutics, Petco Health and Wellness, MillerKnoll And Other Big Stocks Moving Higher On Thursday
March 27, 2025
Via
Benzinga
ImmunityBio to Host Investor Day
March 26, 2025
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Announces First Dosing of Recombinant BCG (rBCG) in the U.S. and 60 Sites Are in the Process of Launching
March 13, 2025
From
ImmunityBio, Inc.
Via
Business Wire
ImmunityBio Analyst Predicts Strong 2025 For New Bladder Cancer Drug
March 06, 2025
HC Wainwright initiates coverage on ImmunityBio with a Buy rating, citing Anktiva's growth potential. The firm projects $4.3 billion in sales, up from $137M in 2025.
Via
Benzinga
This Tourmaline Bio Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Thursday
March 06, 2025
Via
Benzinga
Tesla Rebounds While Tariffs Weigh On Manufacturing: What's Driving Markets Monday?
March 03, 2025
Stocks fell broadly on Monday to start the month of March with all three major indices red in midday trading. Investors digested a decline in February's ISM Manufacturing PMI data which fell to 50.3%,...
Via
Benzinga
ImmunityBio Reports Sales Momentum & Unit Growth Since Permanent J-code Issuance (J9028) in January 2025 and Financial Results for Year End 2024
March 03, 2025
From
ImmunityBio, Inc.
Via
Business Wire
IMMUNITYBIO ALERT: Bragar Eagel & Squire, P.C. is Investigating ImmunityBio, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
February 27, 2025
From
Bragar Eagel & Squire
Via
GlobeNewswire
ImmunityBio Receives FDA RMAT Designation for ANKTIVA® and CAR-NK for the Reversal of Lymphopenia in Patients Receiving Standard-of-Care Chemotherapy/Radiotherapy and in Treatment of Multiply Relapsed Locally Advanced or Metastatic Pancreatic Cancer
February 27, 2025
From
ImmunityBio, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.